title: Feasibility study of cavitation-induced liposomal doxorubicin release in an AT2 Dunning rat tumor model.
abstract: BACKGROUND
  Targeted and triggered release of liposomal drug using heat or ultrasound represents a promising treatment modality able to increase the therapeutic-totoxicity ratio of encapsulated drugs.
  
  
  OBJECTIVE
  To study the ability for high-intensity focused ultrasound to induce liposomal drug release mainly by focused inertial cavitation in vitro and in an animal model.
  
  
  METHODS
  A 1 MHz ultrasound setup has been developed for in vitro and in vivo drug release from a specific liposomal doxorubicin formulation at a target cavitation dose.
  
  
  RESULTS
  Controlled cavitation at 1 MHz was applied within the tumors 48 hours after liposome injection according to preliminary pharmacokinetic study. A small non-significant therapeutic effect of US-liposomal treatment was observed compared to liposomes alone suggesting no beneficial effect of ultrasound in the current setup.
  
  
  CONCLUSIONS
  The in vitro study provided a suitable ultrasound setup for delivering a cavitation dose appropriate for safe liposomal drug release. However, when converting to an in vivo model, no therapeutic benefit was observed. This may be due to a number of reasons, one of which may be the difficulty in converting in vitro findings to an in vivo model. In light of these findings, we discuss important design features for future studies.
authors: INSERM U1032, Université de Lyon, 151 Cours Albert Thomas, Lyon, France. Cyril.lafon@inserm.fr
authors: Cyril
authors: C
authors: Lafon
authors: Lucie
authors: L
authors: Somaglino
authors: Guillaume
authors: G
authors: Bouchoux
authors: Jean Martial
authors: JM
authors: Mari
authors: Sabrina
authors: S
authors: Chesnais
authors: Jacqueline
authors: J
authors: Ngo
authors: Jean-Louis
authors: JL
authors: Mestas
authors: Sigrid L
authors: SL
authors: Fossheim
authors: Esben A
authors: EA
authors: Nilssen
authors: Jean-Yves
authors: JY
authors: Chapelon
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000493:pharmacokinetics* / Q000494:pharmacology*; D016503:Drug Delivery Systems / Q000379:methods; D005240:Feasibility Studies; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism*; D051381:Rats; D014465:Ultrasonics / Q000379:methods
chemical_list: D004317:Doxorubicin